Kamada Ltd 's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Kamada Ltd 's ROA in the fourth quarter of 2025?
Kamada Ltd achieved a return on average assets (ROA) of 5.39 % in its fourth quarter of 2025, which is below Kamada Ltd 's average return on assets, which stands at 5.9%.

ROA decreased relative to the period ending 0, due to the decline in net income.

However, within the Healthcare sector 172 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 1296.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	6.79 %	-19.44 %	-22.01 %	-8.88 %	-37.52 %
Y / Y Net Income Change	-6.46 %	37.1 %	66.65 %	67.61 %	-54.03 %
Net Income (TTM) in million	20	20	19	16	14
Return On Assets (TTM)	5.39 %	5.54 %	4.86 %	3.85 %	3.39 %
KMDA's Total Ranking	# 1296	#	#	#	# 1636
Total Assets (TTM) in million	379	377	368	375	355
Seq. Total Assets Change	0.4 %	2.45 %	-1.85 %	5.78 %	-24.27 %
Seq. Net Income Change	-32.74 %	-28.2 %	86.07 %	4.1 %	-1.42 %

KMDA's 5 Years Annual ROA >> Back to KMDA Management Effectiveness >> Compare KMDA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 64
Sector	# 173
Overall	# 1290

Return On Assets Statistics
High	Average	Low
16.14 %	5.9 %	-0.72 %
(Dec 31 2018)

News about Kamada Ltd Return on Assets ROA

Kamada Ltd.'s Road to Recovery: Facing Financial Challenges and Outlining a Path Forward.

In a recent letter to shareholders, Kamada Ltd., a global biopharmaceutical company based in Rehovot, Israel, and Hoboken, N.J., addressed the company s financial performance and its future outlook. Amir London, the Chief Executive Officer, discussed the challenges faced by the company and outlined its plans moving forward.
One of the key points highlighted in the letter was Kamada Ltd. s recorded net loss of $2 million during the 12 months ending in the fourth quarter of 2022. This resulted in a negative return on assets (ROA) of -1.32%, which raises concerns about the company s profitability. It is important to note that this negative ROA suggests that the company s assets generated lower profits compared to its overall investment.

Financial Statements
Kamada Ltd 's Assets	$ 379 million	KMDA's Balance sheet
Kamada Ltd 's Income	$ 4 million	Quarterly KMDA's Income Statement
KMDA's Income by Division		See KMDA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	2.16 %	-25.98 %	4.29 %	6.35 %	71.94 %
Total Assets in million	362	355	479	459	432
Y / Y Net Income Change	39.66 %	74.58 %	-	-	-
Net Income in million	20	14	8	-2	-2
Annual Return On Assets	5.58 %	4.08 %	1.73 %	-0.51 %	-0.52 %

KMDA's 5 Years Annual ROA >> Back to KMDA Management Effectiveness >> Compare KMDA ROA to its Competitors

Comment on KMDA's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 5.58 % compared to prior year, due to annual net income growth of 39.66 % to $20.20 million, while value of Kamada Ltd 's overall assets grew just by 2.16 % to $362.27 million, compared to $362.27 a year before.

More Return On Assets Ratios
KMDA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KMDA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KMDA's Competitors
Subscribers only: Roa for Kamada Ltd 's Suppliers
Subscribers only: Return On Assets for KMDA's Customers

You may also want to know
KMDA's Roi	KMDA's Inventory Turnover Ratio	KMDA's Growth Rates	KMDA's Dividend Comparisons
	KMDA's Profitability Ratios	KMDA's Asset Turnover Ratio	KMDA's Dividend Growth
KMDA's Roe	KMDA's Valuation Ratios	KMDA's Financial Strength Ratios	KMDA's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector	ROA
Gilead Sciences Inc	14.82 %
Merck and Co Inc	14.64 %
Intuitive Surgical Inc	14.53 %
Strata Critical Medical Inc	14.15 %
Halozyme Therapeutics Inc	14.09 %
Black Diamond Therapeutics Inc	13.91 %
Johnson and Johnson	13.76 %
Harmony Biosciences Holdings inc	13.67 %
Illumina Inc	13.55 %
Waters Corporation	13.35 %
Keros Therapeutics Inc	13.27 %
Prestige Consumer Healthcare Inc	13.25 %
Spero Therapeutics Inc	13.04 %
Hca Healthcare Inc	12.98 %
Novartis Ag	12.59 %
Embecta Corp	12.51 %
Sab Biotherapeutics Inc	12.51 %
Carlisle Companies Incorporated	12.51 %
Aveanna Healthcare Holdings Inc	12.41 %
West Pharmaceutical Services Inc	12.38 %
Inmode Ltd	12.24 %
Dexcom Inc	11.98 %
Corcept Therapeutics Inc	11.87 %
Neurocrine Biosciences Inc	11.62 %
Regeneron Pharmaceuticals Inc	11.51 %
Msa Safety Inc	11.28 %
Alpha Pro Tech Ltd	11.18 %
Lifevantage Corp	11.12 %
Encompass Health Corporation	11.09 %
Lantheus Holdings Inc	10.77 %

Date modified: 2026-09-18T14:10:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.